IceCure Medical Ltd

NasdaqCM ICCM

IceCure Medical Ltd EBIT for the year ending December 31, 2023: USD -15.58 M

IceCure Medical Ltd EBIT is USD -15.58 M for the year ending December 31, 2023, a 6.95% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

IceCure Medical Ltd EBIT for the year ending December 31, 2022 was USD -16.74 M, a -72.14% change year over year.
IceCure Medical Ltd EBIT for the year ending December 31, 2021 was USD -9.72 M, a -134.77% change year over year.
IceCure Medical Ltd EBIT for the year ending December 31, 2020 was USD -4.14 M, a 12.82% change year over year.
IceCure Medical Ltd EBIT for the year ending December 31, 2019 was USD -4.75 M, a -37.60% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqCM: ICCM

IceCure Medical Ltd

CEO	Mr. Eyal Shamir
IPO Date	Aug. 26, 2021
Location	Israel
Headquarters	7 Ha’Eshel Street
Employees	71
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key trends

Past 5 years